Original article| Volume 87, ISSUE 7, P909-913, July 2006

Download started.


Side Effects and Adverse Events Related to Intraligamentous Injection of Sclerosing Solutions (Prolotherapy) for Back and Neck Pain: A Survey of Practitioners


      Dagenais S, Ogunseitan O, Haldeman S, Wooley JR, Newcomb RL. Side effects and adverse events related to intraligamentous injection of sclerosing solutions (prolotherapy) for back and neck pain: a survey of practitioners.


      To study the side effects and adverse events related to intraligamentous injection of sclerosing solutions (prolotherapy) for back and neck pain.


      Practitioner postal survey.


      Postal survey of practitioners of prolotherapy for back and neck pain in the United States and Canada.


      A sample of prolotherapy practitioners from 2 professional organizations were surveyed about their training and experience, use of specific treatment procedures, estimated prevalence of side effects, and adverse events related to prolotherapy for back and neck pain.


      Not applicable.

      Main Outcome Measures

      Prevalence of side effects and adverse events.


      Surveys were completed by 171 practitioners (response rate, 50%). Ninety-eight percent held medical degrees, and 83% were board certified in various disciplines. Respondents had a median of 10 years of experience, during which they had treated a median of 500 patients and given a median of 2000 treatments. Side effects with the highest median estimated prevalence were pain (70%), stiffness (25%), and bruising (5%). There were 472 reports of adverse events, including 69 that required hospitalization and 5 that resulted in permanent injury secondary to nerve injury. The vast majority (80%) were related to needle injuries such as spinal headache (n=164), pneumothorax (n=123), temporary systemic reactions (n=73), nerve damage (n=54), hemorrhage (n=27), nonsevere spinal cord insult (ie, meningitis, paralysis, spinal cord injury) (n=9), and disk injury (n=2).


      Side effects related to prolotherapy for back and neck pain, such as temporary postinjection pain, stiffness, and bruising, are common and benign. Adverse events related to prolotherapy for back and neck pain are similar in nature to other widely used spinal injection procedures. Further study is needed to fully describe the adverse event profile of prolotherapy for back and neck pain.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Archives of Physical Medicine and Rehabilitation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wolsko P.
        • Eisenberg D.M.
        • Davis R.B.
        • Kessler R.
        • Phillips R.S.
        Patterns and perceptions of care for treatment of back and neck pain.
        Spine. 2003; 28 (discussion 298): 292-297
        • Dagenais S.
        • Haldeman S.
        • Wooley J.
        Intraligamentous injection of sclerosing solutions (prolotherapy) for spinal pain.
        Spine J. 2005; 5: 310-328
        • Banks A.
        A rationale for prolotherapy.
        J Orthop Med. 1991; 13: 54-59
        • Quality Care Review Commission
        • California Medical Association
        Multiple injections of sclerosant solution.
        West J Med. 1985; 142: 841
        • US Food and Drug Administration
        What is a serious adverse event?2004 (January 23, Available at: http://www.fda.gov/medwatch/report/DESK/advevnt.htm. Accessed May 9, 2005.)
        • Schneider R.
        • Williams J.J.
        • Liss L.
        Fatality after injection of sclerosing agent to precipitate fibro-osseous proliferation.
        JAMA. 1959; 170: 1768-1772
        • Yelland M.
        • Glasziou P.
        • Bogduk N.
        • Schluter P.
        • McKernon M.
        Prolotherapy injections, saline injections, and exercises for chronic low-back pain.
        Spine. 2004; 29: 9-16
        • Bogduk N.
        Management of chronic low back pain.
        Med J Aust. 2004; 180: 79-83
        • Fitzgibbon D.
        • Posner K.L.
        • Domino K.B.
        • Caplan R.A.
        • Lee L.A.
        • Cheny F.W.
        • American Society of Anesthesiologists
        Chronic pain management.
        Anesthesiology. 2004; 100: 98-105
        • Huston C.
        • Slipman C.
        • Garvin C.
        Complications and side effects of cervical and lumbosacral selective nerve root injections.
        Arch Phys Med Rehabil. 2005; 86: 277-283
        • Lee L.
        Injuries associated with regional anesthesia in the 1980s and 1990s.
        Anesthesiology. 2004; 101: 143-152
        • Nelemans P.
        • deBie R.
        • deVet H.
        • Sturmans F.
        Injection therapy for subacute and chronic benign low back pain.
        Spine. 2001; 26: 501-505
      1. AHFS drug information. American Society of Health System Pharmacists, Bethesda2003
      2. Sweetman S.C. Martindale the complete drug reference. 33rd ed. Pharmaceutical Pr, London2002
      3. Gennaro A.R. Remington the science and practice of pharmacy. 20th ed. Lippincott Williams & Wilkins, Easton2000
        • Ongley M.
        • Klein R.
        • Dorman T.
        • Eek B.
        • Hubert L.
        A new approach to the treatment of chronic low back pain.
        Lancet. 1987; 2: 143-146
        • Dorman T.A.
        J Orthop Med. 1993; 15: 49-50